

# The Future of Open Source: From Drug Discovery to Synthetic Biology

Stephen M. Maurer  
Goldman School of Public Policy  
UC Berkeley

## Why Open Source Matters

## The “Open Source Biology” Idea

### Analogy, Rhetoric, Reality

### Synaptic Leap: How Big is the Landscape?

# A Rational Design Approach

## 1. Background

Definitions

Showstoppers

OS Theory: Incentives & Social Welfare

The Drug Discovery Landscape

## 2. Candidates

## 3. Synthetic Biology

## 4. A (Quick) Word About Licenses

## 5. Synaptic Leap - A Short Infomercial

# 1. Background: Definitions

Definition:

Goal-Oriented Collaboration  
+  
Donated Labor & Materials

# 1. Background: Showstoppers

## The Usual Suspects:

Developing Drugs is Costly

Drug Discovery is a *Pipeline*

Competition With Patent Incentives

A Neglected Disease Niche?

Companies Might *Fund* Open Source

# 1. Background: OS Theory

## Incentives

Ideology

Education and Signaling

Own-Use

- For Hobbies

- For Work

- For Employer

Complementary Goods & Services

Standards Wars

# 1. Background: OS Theory

## Social Welfare

Advantages

(Donated Labor)

Price of Information

Agency Problems/Transparency

Disadvantages

Inadequate Incentives?

# 1. Background:

## The Drug Discovery Landscape

Basic Research  
Finding Targets  
Optimizing Targets  
Finding Lead Compounds  
Optimizing Lead Compounds  
Process Development  
Pre-Clinical Testing  
Phase I Tests  
Phase II Tests  
Phase III Tests  
Approval  
Manufacturing  
Phase IV Tests  
Marketing & Distribution

## 2. Candidates

### Basic Research } Open Science

Finding Targets

Optimizing Targets

Finding Lead Compounds

Optimizing Lead Compounds

Process Development

Pre-Clinical Testing

Phase I Tests

Phase II Tests

Phase III Tests

Approval

Manufacturing

Phase IV Tests

Marketing & Distribution

## 2. Candidates: Open Science

### Examples

BioPERL

HGP, SNP Consortium, HapMap, AfCS.

### Traditional Academic Incentives

Education, Signaling, Own-Use, Ideology.

### Showstoppers?

Physics Precedents

Big Science (*cf.* FermiLab)

Virtual Experiments (PDG, TOI)

### Definitional Objection - Is It Open Source?

HapMap License

## 2. Candidates

Basic Research

Finding Targets

Optimizing Targets

Finding Lead Compounds

Optimizing Lead Compounds

Process Development

Pre-Clinical Testing

Phase I Tests

Phase II Tests

Phase III Tests

Approval

Manufacturing

Phase IV Tests

Marketing & Distribution

} *In Silico* Biology

## 2. Candidates: *In Silico* Biology

### Social Analogy

Biologists ~ Computer Scientists

**Incentives** ~ Education, Signaling  
& Ideology

*A Social* Experiment

### Science Analogy

Doing Science With Databases

*In silico* biology ~ software debugging

*A Scientific* Experiment

## 2. Candidates: *In Silico* Biology

### Social Welfare

Donated Labor

Lower R&D Costs

The SNP Consortium Problem

Lower Manufacturing Costs

Transparency

## 2. Candidates: *In Silico* Biology

Example: Tropical Disease Initiative

Mechanics

On-Line Forums & Running Estimates  
Philosopher Kings?  
Bridging Institutions

## 2. Candidates: *In Silico* Biology

Showstoppers

Competition With Patents

Are *in silico* methods good enough?

Would it Work for Rich Nation Diseases?

## 2. Candidates

Basic Research

Finding Targets

Optimizing Targets

Finding Lead Compounds

Optimizing Lead Compounds

Process Development

Pre-Clinical Testing

Phase I Tests

Phase II Tests

Phase III Tests

Approval

Manufacturing

Phase IV Tests

Marketing & Distribution

} “Wet” Chemistry  
& Biology

## 2. Candidates: Wet Chemistry & Biology

The Reagents Problem

Big Science Grants

“Scrounging Strategies”

- TDI, Benkler

Low Cost, High Ingenuity Problems

- Mat Todd/Schistosomiasis Project

What are the Limits?

## 2. Candidates

Basic Research

Finding Targets

Optimizing Targets

Finding Lead Compounds

Optimizing Lead Compounds

Process Development

Pre-Clinical Testing

Phase I Tests

Phase II Tests

Phase III Tests

Approval

Manufacturing

Phase IV Tests } Off Label Testing

Marketing & Distribution

## 2. Candidates: Off-Label Testing

Examples  
von Hippel Proposal

### Incentives

Ideology, Education & Signaling  
Costs are Already Paid For  
Competition With Patents?

### Social Welfare

Transparency

## 2. Candidates

Basic Research

Finding Targets

Optimizing Targets

Finding Lead Compounds

Optimizing Lead Compounds

Process Development

Pre-Clinical Testing

Phase I Tests

Phase II Tests

Phase III Tests

Approval

Manufacturing

Phase IV Tests

Marketing & Distribution

} Clinical Testing

## 2. Candidates: Clinical Testing

Examples  
(None)

### Incentives

Ideology, Education, Signaling,

Complementary Goods

Patents Would *Support* OS

Advantages

Transparency

## 3. Synthetic Biology

From Garage Science to Standard Parts  
Reading Tea Leaves  
A Chance to Intervene

**Incentives:** Five Stories

Ideology, Education and Signaling,  
Own-Use, **Complementary Goods** &  
**Standards Wars**

### 3. Synthetic Biology: **Incentives**

**Story 1: Ideology, Education, Signaling,  
Own-Use**

**Story 2: Shared Costs**

**Analogy: “Operating Systems vs.  
Applications Programs”**

### 3. Synthetic Biology: Incentives

#### **Story 3: Shared Benefits**

**Analogy: Game Theory  
& Embedded Linux**

**Multiple Possible Equilibria  
Prodding the System**

#### **Story 4: Appropriability May Not Be Valuable**

**Analogy: Software Modules & LINUX**

### 3. Synthetic Biology: Incentives

## **Standards Wars?**

**Parts Repository – Strong Tipping Effects**  
**Private vs. Public Repositories**  
**An Unpredictable Process**

### 3. Synthetic Biology: **Social Welfare**

**Open Standards, Competition, Antitrust  
National Security?**

## 4. License

“Copyright vs. Patents”

The Licensing Fetish

What’s Wrong With the Public Domain?

The Consumer Sovereignty Argument

The Capturing Argument

The Stability Argument

## 4. Licenses

GPL'ing Molecules

Patents vs. Copyright

Filing & Enforcement Costs

Licensing & Waiver Law Issues

Patent Misuse?

Patents & Neglected Diseases

Embargos

Legal Holding Entities

Patent Pools

BIOS/Bioforge

## 5. Infomercial

Steve Maurer [smaurer@berkeley.edu](mailto:smaurer@berkeley.edu)

Computing & On-Line Collaboration:

Ginger Taylor [gtaylor@thesynapticleap.org](mailto:gtaylor@thesynapticleap.org)

Biology:

Marc Marti-Renom [marcius@salilab.org](mailto:marcius@salilab.org)

Chemical Engineering:

Mat Todd [m.todd@chem.usyd.edu.au](mailto:m.todd@chem.usyd.edu.au)

Site: <http://www.thesynapticleap.org/>